UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) – Investment analysts at Jefferies Financial Group issued their Q1 2022 earnings per share (EPS) estimates for shares of UroGen Pharma in a research note issued on Monday, March 21st. Jefferies Financial Group analyst C. Howerton anticipates that the company will post earnings of ($1.58) per share for […]
UroGen Pharma (NASDAQ:URGN – Get Rating) issued its earnings results on Monday. The company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09), MarketWatch Earnings reports. UroGen Pharma had a negative return on equity of 173.25% and a negative net margin of 283.41%. NASDAQ URGN traded down $0.47 during trading […]
UroGen Pharma (NASDAQ:URGN – Get Rating) will announce its earnings results before the market opens on Thursday, March 10th. Analysts expect the company to announce earnings of ($1.23) per share for the quarter. Shares of NASDAQ URGN opened at $6.22 on Tuesday. UroGen Pharma has a fifty-two week low of $5.61 and a fifty-two week […]